Autoantibodies to the dense fine speckled 70 (DFS70) antigen are common among antinuclear antibodies (ANA) positive healthy individuals (HI). We assessed the prevalence of anti-DFS70 antibodies in patients with and without ANA-associated rheumatic diseases (AARDs) by two methods: chemiluminescent immunoassay (CIA) and an indirect immunofluorescence (IIF) assay based on immunoadsorption for DFS70.
Antinuclear antibodies: Is the indirect immunofluorescence still the gold standard or should be replaced by solid phase assays?
Antinuclear antibodies (ANA) are important biomarkers for systemic lupus erythematosus (SLE) and represent a criterion for patient classification. While ANAs are not specific for SLE, patients with SLE are thought to be almost invariably positive.